Drugs Made In America Acquisition Corp

Drugs Made In America Acquisition Corp(DMAA)の株式分析

$10.880

0.000 (0.00%)終値時点

Loading chart…
高値
10.890
始値
10.882
出来高加重平均価格
10.88
出来高
9.48K
時価総額
—
安値
10.880
売買代金
103.20K
EV/EBITDA(TTM)
0.00

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues.

dmaacorp.com

AI分析 of Drugs Made In America Acquisition Corp (DMAA)

中立

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.

バリュエーション指標

Drugs Made In America Acquisition Corp(DMAA)の現在の予想PERは0.00で、5年平均は0.00です。

予想PER

大幅な割安
5年平均 P/E
0.00
現在のP/E
0.00
割高
0.00
割安
0.00

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
0.00
現在のEV/EBITDA
0.00
割高
0.00
割安
0.00

予想PSR

適正
5年平均 P/S
0.11
現在のP/S
0.00
割高
1.18
割安
-0.96

Alphio AI による DMAA の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%DMAA

$10.91

シナリオ価格

基

基本

基本 · 50%DMAA

$9.82

シナリオ価格

弱

弱気

弱気 · 25%DMAA

$9.57

シナリオ価格

DMAA を保有するクジラ

G

Glazer Capital, LLC

+ を保有DMAA

+3.19%

3か月リターン

W

Wolverine Asset Management, LLC

+ を保有DMAA

-16.12%

3か月リターン

DMAA のよくある質問 — Alphio AI が回答

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues. It operates in the Financials sector.

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める